Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors.

Autor: Shields JD; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Aquila BM; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Emmons D; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Finlay MRV; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Gangl ET; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Gu C; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Mlynarski SN; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Petersen J; Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Pop-Damkov P; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Sha L; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Simpson I; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Tavakoli S; Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Tentarelli S; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Wang H; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ye Q; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zheng X; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.

Autor: Tron AE; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Belmonte MA; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA., Adam A; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Surface Oncology, Cambridge, MA, USA., Aquila BM; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Alkermes, Inc., Waltham, MA, USA., Boise LH; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Chiarparin E; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Cidado J; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Embrey KJ; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Gangl E; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Gibbons FD; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Gregory GP; School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3800, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia., Hargreaves D; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Hendricks JA; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Johannes JW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Johnstone RW; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.; The Sir Peter MacCallum Center, Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia., Kazmirski SL; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Fulcrum Therapeutics, Cambridge, MA, USA., Kettle JG; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Lamb ML; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Matulis SM; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Nooka AK; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Packer MJ; Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, SK10 4TG, UK., Peng B; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Rawlins PB; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Robbins DW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Nurix, Inc., San Francisco, CA, USA., Schuller AG; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Su N; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Yang W; Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Ye Q; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Zheng X; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Secrist JP; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA., Clark EA; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Wilson DM; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK., Fawell SE; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA., Hird AW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. alexander.hird@astrazeneca.com.

Publikováno v: Nature communications [Nat Commun] 2018 Dec 17; Vol. 9 (1), pp. 5341. Date of Electronic Publication: 2018 Dec 17.

Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors.

Autor: Hird AW; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States. Electronic address: alexander.hird@astrazeneca.com., Aquila BM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Block MH; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Hennessy EJ; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Kamhi VM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Omer CA; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Laing NM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Saeh JC; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Sha L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Yang B; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2014 Apr 01; Vol. 24 (7), pp. 1820-4. Date of Electronic Publication: 2014 Feb 24.

Discovery of aminopiperidine-based Smac mimetics as IAP antagonists.

Autor: Hennessy EJ; AstraZeneca R&D Boston, Waltham, MA 02451, United States. edward.hennessy@astrazeneca.com, Saeh JC, Sha L, MacIntyre T, Wang H, Larsen NA, Aquila BM, Ferguson AD, Laing NM, Omer CA

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Feb 15; Vol. 22 (4), pp. 1690-4. Date of Electronic Publication: 2011 Dec 31.